Glucose transport dependency defines a therapeutic vulnerability in JAK2V617F-driven myeloproliferative neoplasms. - Weiand P; Chatain N; de Toledo MAS; Moellmann J; Pirker T; Gupta S; Jacobi H; Lazarevic J; Vieri M; Rodriguez MJ; Koschmieder S; Nogueira Gezer D; et al. (Cell communication and signaling : CCS, 2026)